ahlam1399
09-30-2016, 04:51 PM
BRIEF-Endo Pharmaceuticals presents new mid-stage data evaluating safety and effectiveness of Xiaflex
* Endo Pharmaceuticals presents new phase 2 data evaluatingthe safety and effectiveness of Xiaflex(collagenase clostridiumhistolyticum) for dupuytren's disease **duleshttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=BQ1-7oyIUpo:EXyGk_7IVEE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=BQ1-7oyIUpo:EXyGk_7IVEE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=BQ1-7oyIUpo:EXyGk_7IVEE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=BQ1-7oyIUpo:EXyGk_7IVEE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=BQ1-7oyIUpo:EXyGk_7IVEE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/BQ1-7oyIUpo
* Endo Pharmaceuticals presents new phase 2 data evaluatingthe safety and effectiveness of Xiaflex(collagenase clostridiumhistolyticum) for dupuytren's disease **duleshttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=BQ1-7oyIUpo:EXyGk_7IVEE:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=BQ1-7oyIUpo:EXyGk_7IVEE:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=BQ1-7oyIUpo:EXyGk_7IVEE:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=BQ1-7oyIUpo:EXyGk_7IVEE:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=BQ1-7oyIUpo:EXyGk_7IVEE:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/BQ1-7oyIUpo